Back to Search Start Over

Bayer begins phase II study of soluble guanylate cyclase activator, BAY3283142 in patients with chronic kidney disease

Source :
PharmaBiz. August 23, 2024
Publication Year :
2024

Abstract

Bayer announced the start of the ALPINE-1 study, a phase II clinical trial with BAY3283142, an investigational soluble guanylate cyclase (sGC) activator, in patients with chronic kidney disease (CKD). The [...]

Subjects

Subjects :
Bayer AG -- Product development
Medical research
Medicine, Experimental
Chronic kidney failure -- Care and treatment
Clinical trials
Cardiovascular diseases -- Care and treatment
Pharmaceutical industry -- Product development
Pharmaceuticals and cosmetics industries

Details

Language :
English
Database :
Gale General OneFile
Journal :
PharmaBiz
Publication Type :
Periodical
Accession number :
edsgcl.805826210

Tools

Authors Abstract Subjects Details